• 3642 Citations
  • 25 h-Index
19982019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Yasuo Hamamoto is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 39 Similar Profiles
irinotecan Medicine & Life Sciences
Stomach Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Fluorouracil Medicine & Life Sciences
Esophageal Neoplasms Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2019

  • 3642 Citations
  • 25 h-Index
  • 85 Article
  • 5 Review article
  • 3 Letter
  • 2 Comment/debate
1 Citation (Scopus)

A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)

Kato, K., Satoh, T., Muro, K., Yoshikawa, T., Tamura, T., Hamamoto, Y., Chin, K., Minashi, K., Tsuda, M., Yamaguchi, K., Machida, N., Esaki, T., Goto, M., Komatsu, Y., Nakajima, T. E., Sugimoto, N., Yoshida, K., Oki, E., Nishina, T., Tsuji, A. & 11 others, Fujii, H., Kunieda, K., Saitoh, S., Omuro, Y., Azuma, M., Iwamoto, Y., Taku, K., Fushida, S., Chen, L. T., Kang, Y. K. & Boku, N., 2019 Mar 15, In : Gastric Cancer. 22, 2, p. 344-354 11 p.

Research output: Contribution to journalArticle

Open Access
Esophageal Neoplasms
Stomach
Placebos
Drug Therapy
Survival

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial

Yoshikawa, T., Muro, K., Shitara, K., Oh, D. Y., Kang, Y. K., Chung, H. C., Kudo, T., Chin, K., Kadowaki, S., Hamamoto, Y., Hironaka, S., Yoshida, K., Yen, C. J., Omuro, Y., Bai, L. Y., Maeda, K., Ozeki, A., Yoshikawa, R. & Kitagawa, Y., 2019 Aug 2, In : JAMA network open. 2, 8, p. e198243

Research output: Contribution to journalArticle

Open Access
oxaliplatin
Far East
Paclitaxel
Stomach Neoplasms
Randomized Controlled Trials

Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer

Satoh, T., Kang, Y. K., Chao, Y., Ryu, M. H., Kato, K., Cheol Chung, H., Chen, J. S., Muro, K., Ki Kang, W., Yeh, K. H., Yoshikawa, T., Oh, S. C., Bai, L. Y., Tamura, T., Lee, K. W., Hamamoto, Y., Kim, J. G., Chin, K., Oh, D. Y., Minashi, K. & 5 others, Cho, J. Y., Tsuda, M., Tanimoto, M., Chen, L. T. & Boku, N., 2019 Jan 1, In : Gastric Cancer.

Research output: Contribution to journalArticle

Open Access
Esophagogastric Junction
Phase III Clinical Trials
Stomach
Randomized Controlled Trials
Safety
4 Citations (Scopus)

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Kato, K., Cho, B. C., Takahashi, M., Okada, M., Lin, C. Y., Chin, K., Kadowaki, S., Ahn, M. J., Hamamoto, Y., Doki, Y., Yen, C. C., Kubota, Y., Kim, S. B., Hsu, C. H., Holtved, E., Xynos, I., Kodani, M. & Kitagawa, Y., 2019 Nov, In : The Lancet Oncology. 20, 11, p. 1506-1517 12 p.

Research output: Contribution to journalArticle

Drug Therapy
Survival
Interstitial Lung Diseases
Research Personnel
docetaxel
Open Access
Intestinal Perforation
Gastrointestinal Stromal Tumors
Kidney
Cyclosporine
Small Intestine